26186 Efficacy and safety of continuous risankizumab every 12 weeks beyond 3 years of follow-up: An interim analysis of the LIMMitless open-label extension trial

Authors :: Craig L. Leonardi
Jiewei Zeng
Mark Lebwohl
Lluís Puig
Gabriela Alperovich
Simone Rubant
Ranjeeta Sinvhal
Kim A. Papp
Yiwei Zhao
Source :: Journal of the American Academy of Dermatology. 85:AB86
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: medicine.medical_specialty
Risankizumab
business.industry
Physical therapy
medicine
Dermatology
Extension (predicate logic)
Open label
business
Interim analysis

Full Text Access

Tools